Humacyte, Inc. - Common Stock (NQ:HUMA)

0.5000 -0.0200 (-3.85%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Humacyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA

September 04, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Humacyte (HUMA) Q2 2026 Earnings Call Transcript ↗

August 19, 2026

Phase III trial shows 91 more catheter-free days for dialysis patients.

Via The Motley Fool

Topics Earnings

Humacyte Q2 Earnings Call Highlights ↗

August 12, 2026

Humacyte (NASDAQ:HUMA) reported second-quarter commercial sales growth while outlining plans to expand adoption of its SYMVESS vascular repair product, submit a supplemental biologics license...

Via MarketBeat

Topics Earnings

Humacyte Inc (NASDAQ:HUMA) Reports Q4 Revenue Miss, Shares Drop Pre-Market ↗

March 27, 2026

Via Chartmill

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA

August 10, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

July 01, 2026

Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $20.3 million. Humacyte (NASDAQ:HUMA) shares moved upwards by 5.45% to...

Via Benzinga

MultiBagger MicroCaps IGC, RCT, PBK, HUMA, PRSO Stocks to Watch Now

June 30, 2026

Via AB Newswire

Topics Artificial Intelligence

MissionIRNewsBreaks – Humacyte Inc. (NASDAQ: HUMA) Prices $50 Million Public Offering

June 16, 2026

Via Investor Brand Network

Wondering what's happening in today's pre-market session? ↗

June 11, 2026

Via Chartmill

Get insights into the top gainers and losers of Wednesday's after-hours session. ↗

June 10, 2026

Via Chartmill

Humacyte (HUMA) Q1 2025 Earnings Transcript ↗

June 01, 2026

Humacyte (HUMA) Q1 2025 Earnings Transcript

Via The Motley Fool

Humacyte (HUMA) Q1 2026 Earnings Transcript ↗

May 13, 2026

Humacyte (HUMA) Q1 2026 Earnings Transcript

Via The Motley Fool

Humacyte Q1 Earnings Call Highlights ↗

May 13, 2026

Humacyte (NASDAQ:HUMA) reported first-quarter 2026 Symvess sales of $0.5 million and outlined a series of commercial, clinical and cost-reduction initiatives aimed at accelerating adoption of its...

Via MarketBeat

Topics Earnings

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

May 08, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

April 13, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

The market is filled with gapping stocks in Monday's session. ↗

February 09, 2026

Via Chartmill

HUMA Stock Just Shot Up 12% Today – Here’s Everything To Know About The DOD Funding Fueling The Surge ↗

February 09, 2026

The company stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration.

Via Stocktwits

Humacyte (HUMA) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Humacyte (HUMA) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Death Earnings

Humacyte Inc (NASDAQ:HUMA) Beats on EPS but Misses on Revenue in Q3 ↗

November 12, 2025

Humacyte (HUMA) missed Q3 revenue estimates but delivered a smaller-than-expected loss per share. The stock rose as investors focused on its pipeline progress toward key regulatory milestones.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 12, 2025

Via Benzinga

Insights Ahead: Humacyte's Quarterly Earnings ↗

November 11, 2025

Via Benzinga

BioMedNewsBreaks — Humacyte, Inc. (NASDAQ: HUMA) Announces $60 Million Registered Direct Offering of Common Stock and Warrants

October 15, 2025

Via Investor Brand Network

D. Boral Capital Acted as Exclusive Placement Agent to Humacyte (Nasdaq: HUMA) in Connection with its $60,000,000 Registered Direct Offering

October 14, 2025

Via ACCESS Newswire

Top stock movements in today's session. ↗

October 07, 2025

Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 07, 2025

Via Benzinga

Which stocks are moving on Tuesday? ↗

October 07, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Tuesday's session: gap up and gap down stocks ↗

October 07, 2025

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 03, 2025

Via Benzinga

Russell 2000 Hits All-Time Highs: 8 Stocks Power Small-Cap Comeback ↗

September 18, 2025

Small-cap benchmark Russell 2000 ETF hits record high after Fed cuts rates, hinting at more cuts. Small caps rally 43% since tariff-driven selloff.

Via Benzinga

Topics ETFs Economy

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.